Vol 46, No 4 (2008)
Original paper
Submitted: 2011-12-19
Published online: 2009-01-15
Vascular endothelial growth factor (VEGF)-C - a potent risk factor in children diagnosed with stadium 4 neuroblastoma.
Michal Nowicki, Aneta Konwerska, Danuta Ostalska-Nowicka, Katarzyna Derwich, Bogdan Miskowiak, Beata Kondraciuk, Dariusz Samulak, Martin Witt
DOI: 10.2478/v10042-008-0067-7
·
Folia Histochem Cytobiol 2008;46(4):493-499.
Vol 46, No 4 (2008)
ORIGINAL PAPERS
Submitted: 2011-12-19
Published online: 2009-01-15
Abstract
To evaluate the immunohistochemical expression of VEGF-C, CD34 and VEGFR-2 in cancer tissue of children diagnosed with stadium 4 neuroblastoma (NB) and correlate their presence with the survival rate of children diagnosed with that stage of the disease. Eighteen children assigned to stadium 4 composed the study group. Fourteen patients (allocated to stadium 3) formed a control group. VEGF-C, CD34 and VEGFR-2 expressions were evaluated by immunohistochemical assay. Consecutive slides incubated with anti-CD34 and anti-VEGFR-2 antibodies revealed that the two markers were colocalized within endothelial layer of the blood vessels. On the other hand, VEGF-C was expressed exclusively in tumour cells. As demonstrated by Fisher's exact test, the risk of NB treatment failure (progression or relapse) as well as tumour related death, when all the patients were considered, was found to be significant in VEGF-C positive patients. VEGF-C expression in NB constitutes a potent risk factor and may direct future anti-angiogenic treatment strategy. The proximity of VEGF-C and CD34/VEGFR-2 of NB could be the equivalent of a potentially interesting VEGF-C fashion involving a tumour cell invasion into the blood vessels in an early phase of metastases promoting.
Abstract
To evaluate the immunohistochemical expression of VEGF-C, CD34 and VEGFR-2 in cancer tissue of children diagnosed with stadium 4 neuroblastoma (NB) and correlate their presence with the survival rate of children diagnosed with that stage of the disease. Eighteen children assigned to stadium 4 composed the study group. Fourteen patients (allocated to stadium 3) formed a control group. VEGF-C, CD34 and VEGFR-2 expressions were evaluated by immunohistochemical assay. Consecutive slides incubated with anti-CD34 and anti-VEGFR-2 antibodies revealed that the two markers were colocalized within endothelial layer of the blood vessels. On the other hand, VEGF-C was expressed exclusively in tumour cells. As demonstrated by Fisher's exact test, the risk of NB treatment failure (progression or relapse) as well as tumour related death, when all the patients were considered, was found to be significant in VEGF-C positive patients. VEGF-C expression in NB constitutes a potent risk factor and may direct future anti-angiogenic treatment strategy. The proximity of VEGF-C and CD34/VEGFR-2 of NB could be the equivalent of a potentially interesting VEGF-C fashion involving a tumour cell invasion into the blood vessels in an early phase of metastases promoting.
Title
Vascular endothelial growth factor (VEGF)-C - a potent risk factor in children diagnosed with stadium 4 neuroblastoma.
Journal
Folia Histochemica et Cytobiologica
Issue
Vol 46, No 4 (2008)
Article type
Original paper
Pages
493-499
Published online
2009-01-15
Page views
2728
Article views/downloads
1748
DOI
10.2478/v10042-008-0067-7
Bibliographic record
Folia Histochem Cytobiol 2008;46(4):493-499.
Authors
Michal Nowicki
Aneta Konwerska
Danuta Ostalska-Nowicka
Katarzyna Derwich
Bogdan Miskowiak
Beata Kondraciuk
Dariusz Samulak
Martin Witt